Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma, Inc. - Common Stock (NQ:INZY)

1.190 -0.050 (-4.03%)
Streaming Delayed Price Updated: 12:59 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 279,210
Open 1.230
Bid (Size) 1.190 (142)
Ask (Size) 1.200 (21)
Prev. Close 1.240
Today's Range 1.190 - 1.319
52wk Range 0.7210 - 6.240
Shares Outstanding 61,729,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire

Performance

YTD
-58.2%
-58.2%
1 Month
+39.1%
+39.1%
3 Month
-20.7%
-20.7%
6 Month
-71.0%
-71.0%
1 Year
-74.4%
-74.4%

More News

Read More
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
From Inozyme Pharma Inc.
Via GlobeNewswire
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Via Benzinga
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024
Via InvestorPlace
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Inozyme Pharma, Inc. - Common Stock publicly traded?
Yes, Inozyme Pharma, Inc. - Common Stock is publicly traded.
What exchange does Inozyme Pharma, Inc. - Common Stock trade on?
Inozyme Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inozyme Pharma, Inc. - Common Stock?
The ticker symbol for Inozyme Pharma, Inc. - Common Stock is INZY on the Nasdaq Stock Market
What is the current price of Inozyme Pharma, Inc. - Common Stock?
The current price of Inozyme Pharma, Inc. - Common Stock is 1.190
When was Inozyme Pharma, Inc. - Common Stock last traded?
The last trade of Inozyme Pharma, Inc. - Common Stock was at 05/09/25 12:59 PM ET
What is the market capitalization of Inozyme Pharma, Inc. - Common Stock?
The market capitalization of Inozyme Pharma, Inc. - Common Stock is 73.46M
How many shares of Inozyme Pharma, Inc. - Common Stock are outstanding?
Inozyme Pharma, Inc. - Common Stock has 73M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.